Business Wire Feed

Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer

May 21st, 2026|

Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast cancerIRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., a leader in precision oncology for more...

A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer

May 21st, 2026|

Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting provide updates on EVEREST-2 and describe approaches to boost potency and preserve selectivity of TmodTM-based precision cell therapiesCHICAGO--(BUSINESS WIRE)--#ASCO26--A2 Biotherapeutics, Inc. (A2 more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.